Evidence map›Paper›PMID 23796921›Full record

ArticleAntimicrobial agents and chemotherapy2013

Fitness Consequences of

Edwin Ochong, Patrick K Tumwebaze, Oswald Byaruhanga, Bryan Greenhouse, Philip J Rosenthal

2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00948896 phase3completednot on this map

A Randomized Controlled Trial of Monthly Dihydroartemisinin-piperaquine Versus Monthly Sulfadoxine-pyrimethamine Versus Daily Trimethoprim-sulfamethoxazole Versus No Therapy for the Prevention of Malaria

TypeinterventionalSponsorUniversity of California, San FranciscoRan2010 to 2014Enrolled600ConditionsMalariaArmstrimethoprim-sulfamethoxazole (TS, TMP/SMX), sulfadoxine-pyrimethamine (SP), dihydroartemisinin-piperaquine (DP)
NCT00993031 phase3completednot on this map

Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women

TypeinterventionalSponsorUniversity of California, San FranciscoRan2009 to 2013Enrolled389ConditionsMalaria, HIV InfectionsArmsLopinavir/ritonavir, Efavirenz, Zidovudine, Lamivudine
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Reversal of Chloroquine Resistance inInternational journal of molecular sciences · 2026
    Article
  4. Mapping partner drug resistance to guide antimalarial combination therapy policies in sub-Saharan Africa.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  5. Article
  6. Differential Prevalences ofInfection and drug resistance · 2021
    Article
  7. Molecular Mechanisms of Drug Resistance inAnnual review of microbiology · 2020
    Review
  8. Article
  9. Comparative Prevalence ofThe American journal of tropical medicine and hygiene · 2017
    Article
  10. Article
  11. Article
  12. Article
  13. Competition between Plasmodium falciparum strains in clinical infections during in vitro culture adaptation.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2014
    Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Edwin OchongDepartment of Medicine, University of California, San Francisco, California, USA.
Patrick K TumwebazeInfectious Diseases Research Collaboration, Kampala, Uganda.
Oswald ByaruhangaInfectious Diseases Research Collaboration, Kampala, Uganda.
Bryan GreenhouseDepartment of Medicine, University of California, San Francisco, California, USA.
Philip J RosenthalDepartment of Medicine, University of California, San Francisco, California, USA prosenthal@medsfgh.ucsf.edu.
University of California, San Francisco · USInfectious Diseases Research Collaboration · UG

Funding

Transmission ProjectU19AI089674 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MATTHEW G DORSEY, MOSES Robert KAMYA · 2010 to 2026
$29.3M
The immunologic consequences of prenatal exposure to malariaP01HD059454 · NICHD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHARLEBOIS, EDWIN DUNCAN · 2008 to 2017
$22.6M
Resistance of Malaria Parasites to Artemisinin-Based TherapiesR01AI075045 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENTHAL, PHILIP JON · 2009 to 2024
$8.4M
Training In Malaria Research in UgandaD43TW007375 · FIC · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENTHAL, PHILIP JON · 2005 to 2019
$2.9M
Resistance of Malaria Parasites to Artemisinin-Based Combination TherapiesR56AI075045 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENTHAL, PHILIP JON · 2008 to 2008
$618k
FIC NIH HHS D43 TW007375NIAID NIH HHS R01 AI075045NIAID NIH HHS R56 AI075045NIAID NIH HHS U19 AI089674NICHD NIH HHS P01 HD059454
6 · The paper itself

Abstract

Polymorphisms in the

Identifiers

PMID23796921
PMCPMC3754360
OpenAlexW2124167525

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.